Skip to main content
SpringerLink
Log in

A priori prediction of ligand affinity by energy minimization

  • Published:
Perspectives in Drug Discovery and Design

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kollman, P., Free energy calculation: Applications to chemical and biochemical phenomena, Chem. Rev., 93 (1993) 2395–2417.

    Google Scholar 

  2. Oprea, T.I., Waller, C.L. and Marshall, G.R., 3-dimensional quantitavie structure-activity relationship of human-immunodeficiency-virus-(I) protease inhibitors: 2. Predictive power using limited exploration of alternate binding modes, J. Med. Chem., 37 (1994) 2206–2215.

    Google Scholar 

  3. Waller, C.L., Oprea, T.I., Giolitti, A. and Marshall, G.R., 3-dimensional QSAR of human-immunodeficiency-virus-(I) protease inhibitors: 1. A COMFA study employing experimentally-determined alignment rules, J. Med. Chem., 36 (1993) 4152–4160.

    Google Scholar 

  4. Doweyko, A.M., Three-dimensional pharmacophores from binding data, J. Med. Chem., 37 (1994) 1769–1778.

    Google Scholar 

  5. Meng, E.C., Kuntz, I.D., Abraham, D.J. and Kellogg, G.E., Evaluating docked complexes with the HINT exponential function and empirical atomic hydrophobicities, J. Comput.-Aided Mol. Design, 8 (1994) 299–306.

    Google Scholar 

  6. Nauchitel, V., Villaverde, M.C. and Sussman, F., Solvent accessibility as a predictive tool for the free-energy of inhibitor binding to the HIV-1 protease, Protein Science, 4 (1995) 1356–1364.

    Google Scholar 

  7. Wang, H. and Ben-Naim, A., A possible involvement of solvent-induced interactions in drug design, J. Med. Chem., 39 (1996) 1531–1539.

    Google Scholar 

  8. Wallqvist, A., Jernigan, R.L. and Covell, D.G., A preference-based free-energy parameterization of enzyme-inhibitor binding: Applications to HIV-1 protease inhibitor design, Protein Science, 4 (1995) 1881–1903.

    Google Scholar 

  9. Wallqvist, A. and Covell, D.G., Docking enzyme-inhibitor complexes using a preference-based free-energy surface, Proteins: Struct., Funct. Gene., 25 (1996) 403–419.

    Google Scholar 

  10. Verkhivker, G., Appelt, K., Freer, S.T., and Villafranca, J.E., Empirical free energy calculations of ligand-protein crystallographic complexes: I. Knowledge-based ligand-protein interaction potentials applied to the prediction of human immunodeficiency virus 1 protease binding affinity, Protein Eng., 8 (1995) 677–691.

    Google Scholar 

  11. Verkhivker, G.M. and Rejto, P.A., A mean field model of ligand-protein interactions: Implications for the structural assessment of human immunodeficiency virus type I protease complexes and receptor-specific binding, Proc. Natl. Acad. Sci. USA, 93 (1996) 60–64.

    Google Scholar 

  12. Meng, E.C. Shoichet, B.K. and Kuntz, I.D., Automated docking with grid-based energy evaluation, J. Comput. Chem., 13 (1992) 505.

    Google Scholar 

  13. Verlinde, C.L.M.J., Rudenko, G., and Wim, G.J.H., In search of new lead compounds for trypano-somiasis drug design: a protein structure-based linked-fragment approach, J., Comput.-Aided Mol. Design, 6 (1992) 131–147.

    Google Scholar 

  14. Rotstein, S.H. and Murcko, M.A., Groupbuild: A fragment-based method for de novo drug design, J. Med. Chem., 36 (1993) 1700–1710.

    Google Scholar 

  15. Böhm, H.-J., The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure, J. Comput.-Aided Mol. Design, 8 (1994) 243–256.

    Google Scholar 

  16. Bohacek, R.S.; McMartin, C., De novo design of highly diverse structures complementary to enzyme binding sites: Application to thermolysin, In Reynolds, C.H., Holloway, M.K. and Cox, H.K., (Eds.) Computer-aided molecular design: Applications in agrochemicals, materials and pharmaceuticals, ACS Symposium series 589, American Chemical Society, Washington, DC, 1995, pp. 82–97.

    Google Scholar 

  17. Head, R.D., Smythe, M.L., Oprea, T.I., Waller, C.L., Green, S.M. and Marshall, G.R., VALIDATE: A new method for the receptor-based prediction of binding affinities of novel ligands, J. Am. Chem. Soc., 118 (1996) 3959–3969.

    Google Scholar 

  18. Ortiz, A.R., Pisabarro, M.T., Gago, F. and Wade, R.C., Prediction of drug binding affinities by comparative binding energy analysis, J. Med. Chem., 38 (1995) 2681–2691.

    Google Scholar 

  19. Vajda, S., Weng, Z., Rosenfeld, R. and DeLisi, C., Effect of conformational flexibility and solvation on receptor-ligand binding free energies, Biochemistry, 33 (1994) 13977–13988.

    Google Scholar 

  20. King, B.L., Vajda, S. and Delisi, C., Empirical free-energy as a target function in docking and design: Application to HIV-1 protease inhibitors, FEBS Lett., 384 (1996) 87–91.

    Google Scholar 

  21. Taylor, N.R. and von Itzstein, M., Molecular modeling studies on ligand-binding to sialidase from influenza virus and the mechanism of catalysis, J. Med. Chem., 37 (1994) 616–624.

    Google Scholar 

  22. De Winter, H.L., and von Itzstein, M., Aldose reductase as a target for drug design-Molecular modeling calculations on the binding of acyclic sugar substrates to the enzyme, Biochemistry, 34 (1995) 8299–8308.

    Google Scholar 

  23. Grootenhuis, P.D.J. and van Galen, P.J.M., Correlation of binding affinities with nonbonded interaction energies of thrombin-inhibitor complexes, Acta Cryst., D51 (1995) 560–566.

    Google Scholar 

  24. Kurinov, I.V. and Harrison, R.W., Prediction of New Serine Proteinase Inhibitors, Structural Biology, 1 (1994) 735–743.

    Google Scholar 

  25. Sansom, C.E., Wu, J. and Weber, I.T., Molecular mechanics analysis of inhibitor binding to HIV-1 protease, Protein Eng., 5 (1992) 659–667.

    Google Scholar 

  26. Weber, I.T., Harrison, R.W., Molecular mechanics calculations on HIV-1 protease with peptide-substrates correlate with experimental data, Protein Eng., 9 (1996) 679–690.

    Google Scholar 

  27. Miertus, S., Furlan, M., Tossi, A. and Romeo, D., Design of new inhibitors of HIV-1 aspartic protease, Chem. Phys., 204 (1996) 173–180.

    Google Scholar 

  28. Tossi, A., Furlan, M., Antcheva, N., Romeo, D. and Miertus, S., Efficient inhibition of HIV-1 aspartic protease by synthetic, computer designed peptide mimetics, Minerva Biotec., 8 (1996) 165–171.

    Google Scholar 

  29. Viswanadhan, V.N., Reddy, M.R., Wlodawer, A., Varney, M.D. and Weinstein, J.N., An approach to rapid estimation of relative binding affinities of enzyme inhibitors: Application to peptidomimetic inhibitors of the human immunodeficiency virus type I protease, J. Med. Chem., 39 (1996) 705–712.

    Google Scholar 

  30. Holloway, M.K., Wai, J.M., Halgren, T.A., Fitzgerald, P.M.D., Vacca, J.P., Dorsey, B.D., Levin, R. B., Thompson, W.J., Chen, L.J., Desolms, S.J., Gaffin, N., Ghosh, A.K., Giuliani, E.A., Graham, S.L., Guare, J.P., Hungate, R.W., Lyle, T.A., Sanders, W.M., Tucker, T.J., Wiggins, M., Wiscount, C.M., Woltersdorf, O.W., Young, S.D., Darke, P.L., and Zugay, J.A., A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site, J. Med. Chem., 38 (1995) 305–317.

    Google Scholar 

  31. Holloway, M.K. and Wai, J.M., Structure-based design of human immunodeficiency virus-1 protease inhibitors: Correlating calculated energy with activity, In Reynolds, C.H., Holloway, M.K., and Cox, H.K. (Eds.) Computer-aided molecular design: Applications in agrochemicals, materials, and pharmaceuticals, ACS Symposium series 589, American Chemical Society, Washington, DC, 1995, pp. 36–50.

    Google Scholar 

  32. Thompson, W.J., Fitzgerald, P.M.D., Holloway, M.K., Emini, E.A., Darke, P.L., McKeever, B.M., Schleif, W.A., Quintero, J.C., Zugay, J.A., Tucker, T.J., Schwering, J.E., Homnick, C.F., Nunberg, J., Springer, J.P. and Huff, J.R., Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1, phenyl sustituents: X-ray crystal structure assisted design, J. Med. Chem., 35 (1992) 1685–1701.

    Google Scholar 

  33. Hofmann, T., Hodges, R.S. and James, M.N.G., Effect of pH on the activities of Penicillopepsin and Rhizopus pepsin and a proposal for the productive substrate binding mode in Penicillopepsin, Biochemistry, 23 (1984) 635–643.

    Google Scholar 

  34. Hyland, L.J., Tomaszek, T.A., Jr. and Meek, T.D., Human immunodeficiency virus-1 protease: 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism, Biochemistry, 30 (1991) 8454–8463.

    Google Scholar 

  35. CHARMm version 21.1.7b.; available from Molecular Simulations, Inc., Burlington, MA, U.S.A.

  36. Available from W. Clark Still, Department of Chemistry, Columbia University, New York, U.S.A.

  37. Allinger, N.L., Conformational analysis. 130. MM2: A hydrocarbon force field utilizing V1 and V2 torsional terms, J. Am. Chem. Soc., 99 (1977) 8127.

    Google Scholar 

  38. Lam, P.Y.S., Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors, Science, 263 (1994) 380–384.

    Google Scholar 

  39. Thaisrivongs, S., Random and Rational: Lead Generation via Rational Drug Design and Combinatorial Chemistry, New York, 19–20 October 1994.

  40. Vacca, J.P., Fitzgerald, P.M.D., Holloway, M.K., Hungate, R.W., Starbuck, K.E., Chen, L.J., Darke, P.L., Anderson, P.S., and Huff, J.R., Conformationally constrained HIV-1 protease inhibitors, Bioorg. Med. Chem. Lett., 4 (1994) 499–504.

    Google Scholar 

  41. Ghosh, A.K., Thompson, W.J., Fitzgerald, P.M.D., Culberson, J.C., Axel, M.G., McKee, S.P., Huff, J.R. and Anderson, P.S., Structure-based design of HIV-1 protease inhibitors: Replacement of two amides and a 10≠-aromatic system by a fused bis-tetrahydrofuran, J. Med. Chem., 37 (1994) 2506–2508.

    Google Scholar 

  42. Chen, Z., Li, Y., Chen, E., Hall, D.L., Darke, P.L, Culberson, J.C., Shafer, J. and Kuo, L.C., Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524; An orally bioavailable inhibitor of the HIV protease, J. Biol. Chem., 269 (1994) 26344–26348.

    Google Scholar 

Download references

Authors
  1. M. Katharine Holloway
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holloway, M.K. A priori prediction of ligand affinity by energy minimization. Perspectives in Drug Discovery and Design 9, 63–84 (1998). https://doi.org/10.1023/A:1027251719816

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1027251719816

Keywords

Search

Navigation